$NXEN
Nexien Biopharma Inc

2023 Q2 Form 10-Q Financial Statement

#000149315223017925 Filed on May 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $70.00K $69.38K $164.4K
YoY Change -1.62% -57.8% -175.17%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $70.00K $69.38K $164.4K
YoY Change -1.62% -57.8% -175.17%
Operating Profit
YoY Change
Interest Expense -$30.00K -$10.48K -$23.05K
YoY Change 16.05% -54.53% 206.52%
% of Operating Profit
Other Income/Expense, Net -$10.48K -$23.05K
YoY Change -54.54%
Pretax Income -$90.00K -$79.85K -$187.5K
YoY Change -7.22% -57.4% -188.75%
Income Tax
% Of Pretax Income
Net Earnings -$90.00K -$79.85K -$187.5K
YoY Change -7.22% -57.4% -188.75%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$3.173K
COMMON SHARES
Basic Shares Outstanding 63.52M shares 62.77M shares 59.08M shares
Diluted Shares Outstanding 62.64M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $54.21K $140.2K
YoY Change -100.0% -61.34% 358.84%
Cash & Equivalents $35.15K $54.21K $140.2K
Short-Term Investments
Other Short-Term Assets $0.00 $3.990K $3.810K
YoY Change -100.0% 4.72% 27.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.13K $58.20K $144.0K
YoY Change -65.36% -59.59% 329.17%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $43.13K $58.20K $144.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $43.13K $58.20K $144.0K
YoY Change -65.36% -59.59% 329.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00 $22.41K $13.10K
YoY Change -100.0% 71.07% 151.44%
Accrued Expenses $0.00 $45.00K $45.00K
YoY Change -100.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $200.0K $221.1K $149.2K
YoY Change 13.17% 48.2%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $295.1K $288.5K $207.3K
YoY Change 21.89% 39.18% 3878.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $295.1K $288.5K $207.3K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $295.1K $288.5K $207.3K
YoY Change 21.89% 39.18% 1525.8%
SHAREHOLDERS EQUITY
Retained Earnings -$11.30M -$11.20M
YoY Change 3.31%
Common Stock $6.402K $6.277K
YoY Change 5.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$252.0K -$230.3K -$63.26K
YoY Change
Total Liabilities & Shareholders Equity $43.13K $58.20K $144.0K
YoY Change -65.36% -59.59% 329.17%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$90.00K -$79.85K -$187.5K
YoY Change -7.22% -57.4% -188.75%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$20.00K -$14.78K -$21.72K
YoY Change -14.24% -31.95% 23.55%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 159.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -20.00K -14.78K -21.72K
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 0.000 159.0K
Net Change In Cash -20.00K -14.78K 137.3K
YoY Change -14.24% -110.77% -880.89%
FREE CASH FLOW
Cash From Operating Activities -$20.00K -$14.78K -$21.72K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63522196 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54207 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116898 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3990 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7620 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
58197 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
124518 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001625288
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q1 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2022Q2 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2022Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
NXEN Fair Value Of Shares Issued For Acquisition
FairValueOfSharesIssuedForAcquisition
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55320
dei Entity Registrant Name
EntityRegistrantName
NEXIEN BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2049376
dei Entity Address Address Line1
EntityAddressAddressLine1
4340 E Kentucky Ave.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 206
dei Entity Address City Or Town
EntityAddressCityOrTown
Glendale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80246
dei City Area Code
CityAreaCode
(303)
dei Local Phone Number
LocalPhoneNumber
495-7583
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 us-gaap Assets
Assets
58197 usd
CY2022Q2 us-gaap Assets
Assets
124518 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
22407 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20395 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
45000 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
45000 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
14365 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
30452 usd
CY2023Q1 NXEN Convertible Notes Payable Related Party
ConvertibleNotesPayableRelatedParty
50635 usd
CY2022Q2 NXEN Convertible Notes Payable Related Party
ConvertibleNotesPayableRelatedParty
34548 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
28274 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
170454 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
142180 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
288496 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
242123 usd
CY2023Q1 us-gaap Liabilities
Liabilities
288496 usd
CY2022Q2 us-gaap Liabilities
Liabilities
242123 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62772196 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62772196 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60522196 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60522196 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6277 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
6052 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10914451 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10759051 usd
CY2023Q1 NXEN Stock Payable
StockPayable
50750 usd
CY2022Q2 NXEN Stock Payable
StockPayable
50750 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11201777 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10933458 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-230299 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-117605 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58197 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124518 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
8760 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
11290 usd
us-gaap Professional Fees
ProfessionalFees
30180 usd
us-gaap Professional Fees
ProfessionalFees
28770 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60615 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
153113 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
186542 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
464068 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
69375 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
164403 usd
us-gaap Operating Expenses
OperatingExpenses
216722 usd
us-gaap Operating Expenses
OperatingExpenses
492838 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
2393 usd
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
9352 usd
us-gaap Interest Expense Other
InterestExpenseOther
7236 usd
us-gaap Interest Expense Other
InterestExpenseOther
11959 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8085 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13696 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
44361 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
24559 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10478 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23048 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-51597 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-36518 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-79853 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-187451 usd
us-gaap Net Income Loss
NetIncomeLoss
-268319 usd
us-gaap Net Income Loss
NetIncomeLoss
-529356 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.003
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.004
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62637365 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59080529 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61868350 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57009375 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-117605 usd
CY2022Q3 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2022Q3 NXEN Adjustments To Additional Paid In Capital Imputed Interest On Related Party Advances
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyAdvances
1125 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-94874 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-160604 usd
CY2022Q4 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2022Q4 NXEN Adjustments To Additional Paid In Capital Imputed Interest On Related Party Advances
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyAdvances
1125 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-93592 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-202321 usd
CY2023Q1 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2023Q1 NXEN Adjustments To Additional Paid In Capital Imputed Interest On Related Party Advances
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyAdvances
1125 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-79853 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-230299 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-13775 usd
CY2021Q3 us-gaap Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
60000 usd
CY2021Q3 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
35500 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-121711 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-39986 usd
CY2021Q4 us-gaap Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
163255 usd
CY2021Q4 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
35000 usd
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
500 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-220194 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-62425 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-62425 usd
CY2022Q1 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
35000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
110264 usd
CY2022Q1 NXEN Stock Issued During Period Exercise Of Warrant Issued For Consulting Services
StockIssuedDuringPeriodExerciseOfWarrantIssuedForConsultingServices
2250 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
26500 usd
CY2022Q1 NXEN Adjustments To Additional Paid In Capital Warrant Issued For Convertible Debt
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForConvertibleDebt
12602 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-187451 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-63260 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-63260 usd
us-gaap Net Income Loss
NetIncomeLoss
-268319 usd
us-gaap Net Income Loss
NetIncomeLoss
-529356 usd
NXEN Fair Value Of Shares Issued For Acquisition
FairValueOfSharesIssuedForAcquisition
223255 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
110264 usd
NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
3375 usd
NXEN Stock Issued To Officers And Director
StockIssuedToOfficersAndDirector
152250 usd
NXEN Stock Issued To Officers And Director
StockIssuedToOfficersAndDirector
105000 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
16087 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
16205 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
28274 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12389 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3630 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3690 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2012 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6729 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62691 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51824 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
146750 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2250 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
25000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62691 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
122176 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
116898 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18041 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54207 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140217 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11201777 usd
CY2023Q1 NXEN Working Capital Deficit
WorkingCapitalDeficit
230299 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_znr6NRAeRSO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zpW4mBCHwxfh">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z9x8BJvy35Fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zodV6nehJ0Q3">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Advertising Expense
AdvertisingExpense
0 usd
us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P3Y8M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2022Q2 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Term4
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerm4
P3Y4M9D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2023Q1 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y7M6D
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
170454 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
142180 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
28274 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
28274 usd
CY2023Q1 NXEN Convertible Notes Payable Related Party
ConvertibleNotesPayableRelatedParty
50635 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
14365 usd
CY2022Q2 NXEN Convertible Notes Payable Related Party
ConvertibleNotesPayableRelatedParty
34548 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
30452 usd
NXEN Amortization Of Beneficial Conversion Feature
AmortizationOfBeneficialConversionFeature
16087 usd
NXEN Amortization Of Beneficial Conversion Feature
AmortizationOfBeneficialConversionFeature
16205 usd
CY2023Q1 NXEN Convertible Notes Payable Related Party
ConvertibleNotesPayableRelatedParty
50635 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
14365 usd
CY2022Q2 NXEN Convertible Notes Payable Related Party
ConvertibleNotesPayableRelatedParty
34548 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
30452 usd

Files In Submission

Name View Source Status
0001493152-23-017925-index-headers.html Edgar Link pending
0001493152-23-017925-index.html Edgar Link pending
0001493152-23-017925.txt Edgar Link pending
0001493152-23-017925-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
nxen-20230331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
nxen-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
nxen-20230331_cal.xml Edgar Link unprocessable
nxen-20230331_lab.xml Edgar Link unprocessable
nxen-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending